The creation of retatrutide, a novel dual activator targeting both GLP-1 and GIP receptors, represents a complex several-stage organic process. Early routes focused on peptide portion coupling, utilizing solid-phase creation methodologies to build the long peptide sequence. Subsequent study has explored different approaches, including enzymatic pro